The Winship Cancer Institute of Emory University (Winship) was awarded a type I Cancer Center Support Grant (CCSG) in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care. The 152 Winship members are actively engaged in one of four research programs: Cancer Genetics and Epigenetics, Cancer Cell Biology, Discovery and Developmental Therapeutics, and Cancer Prevention and Control. Winship's members are supported by five shared resources: Cell Imaging and Microscopy, Cancer Genomics, Biostatistics and Bioinformatics, Cancer Tissue and Pathology, and the Clinical Trials Office. Winship currently occupies more than 482k sq. ft. (sf) of dedicated clinical, research, and shared resource space under the direct control of the Executive Director, Walter J. Curran, Jr. M.D. Dr. Curran assumed this position in Sept. 2009 and under his leadership Winship completed a five-year strategic plan, a full reorganization of the senior leadership and administrative infrastructure, and an expansion of the pilot grant program to reward mentorship, inter-programmatic collaboration, innovation in clinical research, and outstanding junior investigators. Winship's 4 research programs have also undergone full re-evaluation and re-invigoration with the addition of several new program leaders and co-leaders, improved member alignment, more focused scientific themes, and greater program leader participation in cancer center decision-making and governance. Since its initial CCSG application Winship has experienced significant research growth and maturation. Total cancer-related peer-reviewed grant funding has increased 35% to $74.6 million, and NCI funding has increased 21% to $29.5 million. Currently there are 19 federally-supported multi-investigator cancer-relevant grants led by Winship members. Winship has outstanding institutional commitment, with more than $115 million in institutional support over the next five years (more than twice that committed in 2008), with its institutional status at the level of Emory's Schools of Medicine, Public Health, and Nursing. Plans are in place for an additional 57K sf of cancer research space. Patient enrollment in Winship's innovative therapeutic and non-therapeutic trials continues to increase, especially among patients from under-represented minority groups. Winship is well-positioned to leverage its growth and development as an NCI-designated cancer center into fulfilling its vision of transformative cancer research and care.
Winship was awarded a type I CCSG in April 2009. This application represents the first competitive renewal seeking support for years 4-9. Winship is a research university-based matrix cancer center with a vision to be a transformative leader in integrating cancer research care.
|Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94|
|Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42|
|Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527|
|Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81|
|Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68|
|Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64|
|Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16|
|Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111|
|Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41|
|Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822|
Showing the most recent 10 out of 210 publications